Pfizer drug extends life for people with rare form of lung cancer

A Pfizer lung cancer drug has been shown to greatly reduce tumour progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday. — AFP picWASHINGTON, June 2 — A Pfizer lung cancer drug has been shown to greatly reduce tumour progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday.

Sixty percent of patients receiving lorlatinib, an oral one a day tablet, were alive without disease progression after five years compared to 8 per cent on crizotinib.NSCLC accounts for more than 80 per cent of lung cancers, with ALK-positive tumours responsible for roughly 5 per cent of NSCLC cases, translating to around 72,000 new cases each year worldwide.

Patients on the lorlatinib arm had a 94 per cent risk reduction in the progression of brain metastases compared to crizotinib.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Socso's 'Amnesty Month' initiative extended till June 30, says HR MinisterBANDAR SERI BEGAWAN: The Sultanate is among the 10 countries to have reduced road traffic deaths by over 50 per cent, according to World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus in Geneva, Switzerland on Monday (May27).
Source: staronline - 🏆 4. / 75 Read more »